Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 18 | 2025 | 374 | 4.500 |
Why?
|
| Brain Neoplasms | 24 | 2025 | 1410 | 4.030 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2025 | 1304 | 1.420 |
Why?
|
| Glioma | 4 | 2022 | 535 | 1.410 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2025 | 82 | 1.380 |
Why?
|
| Astrocytoma | 2 | 2022 | 112 | 1.360 |
Why?
|
| Meningeal Neoplasms | 6 | 2024 | 216 | 1.120 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2020 | 3 | 0.670 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 185 | 0.670 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1161 | 0.660 |
Why?
|
| Meningioma | 4 | 2024 | 141 | 0.610 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 57 | 0.590 |
Why?
|
| Research Design | 2 | 2023 | 743 | 0.570 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 13 | 0.560 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2015 | 226 | 0.560 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 215 | 0.520 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 382 | 0.510 |
Why?
|
| Ganglioglioma | 1 | 2016 | 22 | 0.500 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2025 | 3853 | 0.460 |
Why?
|
| Blindness | 1 | 2015 | 76 | 0.450 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 486 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 559 | 0.420 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 109 | 0.410 |
Why?
|
| West Nile virus | 1 | 2015 | 117 | 0.410 |
Why?
|
| West Nile Fever | 1 | 2015 | 139 | 0.400 |
Why?
|
| Humans | 47 | 2025 | 132257 | 0.390 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 257 | 0.380 |
Why?
|
| Epilepsy | 1 | 2020 | 891 | 0.380 |
Why?
|
| Neuroimaging | 1 | 2015 | 375 | 0.360 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 24 | 0.350 |
Why?
|
| Adult | 20 | 2025 | 31620 | 0.330 |
Why?
|
| Mutation | 7 | 2025 | 6250 | 0.330 |
Why?
|
| Neoplasms | 4 | 2019 | 2961 | 0.320 |
Why?
|
| Body Height | 2 | 2021 | 204 | 0.320 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 258 | 0.310 |
Why?
|
| Aged | 15 | 2025 | 21484 | 0.300 |
Why?
|
| Middle Aged | 19 | 2025 | 29027 | 0.280 |
Why?
|
| Electroencephalography | 3 | 2020 | 908 | 0.280 |
Why?
|
| Retrospective Studies | 15 | 2024 | 17396 | 0.280 |
Why?
|
| Bevacizumab | 3 | 2017 | 80 | 0.270 |
Why?
|
| Female | 23 | 2025 | 70792 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1295 | 0.220 |
Why?
|
| Young Adult | 9 | 2021 | 9970 | 0.220 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1829 | 0.220 |
Why?
|
| Benchmarking | 1 | 2025 | 138 | 0.220 |
Why?
|
| Male | 20 | 2025 | 65019 | 0.210 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2023 | 21 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 605 | 0.190 |
Why?
|
| Olivary Nucleus | 1 | 2022 | 11 | 0.190 |
Why?
|
| Cerebellar Nuclei | 1 | 2022 | 14 | 0.190 |
Why?
|
| Headache | 2 | 2020 | 110 | 0.190 |
Why?
|
| Hypertrophy | 1 | 2022 | 101 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 84 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2019 | 145 | 0.180 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 122 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 122 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2166 | 0.180 |
Why?
|
| Melanoma | 2 | 2022 | 954 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 297 | 0.180 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2021 | 7 | 0.170 |
Why?
|
| JC Virus | 1 | 2021 | 29 | 0.170 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 42 | 0.170 |
Why?
|
| Ependymoma | 1 | 2022 | 177 | 0.170 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 37 | 0.170 |
Why?
|
| Frontal Bone | 1 | 2020 | 16 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2019 | 1575 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 7140 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2019 | 23 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2019 | 5 | 0.160 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 26 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 902 | 0.150 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 13 | 0.150 |
Why?
|
| Optic Nerve Glioma | 1 | 2019 | 22 | 0.150 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 18 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 87 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 89 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2018 | 59 | 0.140 |
Why?
|
| Telomerase | 1 | 2019 | 168 | 0.140 |
Why?
|
| Algorithms | 1 | 2025 | 1725 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 608 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 144 | 0.140 |
Why?
|
| Erdheim-Chester Disease | 1 | 2017 | 28 | 0.140 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2017 | 17 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 15 | 0.130 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2017 | 20 | 0.130 |
Why?
|
| Third Ventricle | 1 | 2017 | 32 | 0.130 |
Why?
|
| Hemangioma, Cavernous | 1 | 2017 | 20 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 956 | 0.130 |
Why?
|
| Prognosis | 4 | 2019 | 5016 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 317 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 109 | 0.120 |
Why?
|
| Pandemics | 1 | 2024 | 1186 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2017 | 276 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1128 | 0.120 |
Why?
|
| Gliosarcoma | 1 | 2015 | 10 | 0.120 |
Why?
|
| Survival Rate | 2 | 2018 | 2196 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 223 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1284 | 0.120 |
Why?
|
| Incidence | 3 | 2020 | 3377 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2019 | 13031 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2017 | 277 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3018 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1034 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 412 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2021 | 6569 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2021 | 5176 | 0.100 |
Why?
|
| Wound Healing | 1 | 2015 | 475 | 0.090 |
Why?
|
| Israel | 2 | 2021 | 48 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 702 | 0.090 |
Why?
|
| Time Factors | 3 | 2018 | 6452 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1134 | 0.080 |
Why?
|
| Risk Factors | 4 | 2021 | 10946 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1541 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 103 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 20561 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5412 | 0.050 |
Why?
|
| Age Factors | 2 | 2019 | 2923 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2022 | 37 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 651 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 118 | 0.050 |
Why?
|
| Dimethyl Fumarate | 1 | 2021 | 10 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 222 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 200 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2022 | 208 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3736 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 125 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 571 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 72 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 576 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 348 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 124 | 0.040 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 37 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 813 | 0.030 |
Why?
|
| Dura Mater | 1 | 2017 | 26 | 0.030 |
Why?
|
| Linear Models | 1 | 2019 | 714 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 165 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 376 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2019 | 217 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 673 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1354 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 185 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 436 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 692 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 47 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 117 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 689 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 115 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1700 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1250 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 551 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 396 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 296 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1591 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 816 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 770 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2233 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2139 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 804 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7557 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 3194 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 34850 | 0.010 |
Why?
|